Login to Your Account

Clinic Roundup

Tuesday, July 2, 2013
• Halozyme Therapeutics Inc., of San Diego, reported interim results from a proof-of-concept Phase I/II trial evaluating the activity and local tolerability of HTI-501, an investigational biologic, for use in aesthetic dermatology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription